A carregar...

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

INTRODUCTION: Concurrent signal transduction inhibition with the epidermal growth factor receptor (EGFR) inhibitor gefitinib and the mammalian target-of-rapamycin inhibitor everolimus has been hypothesized to result in enhanced antitumor activity in patients with non-small cell lung cancer (NSCLC)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Price, Katharine A., Azzoli, Christopher G., Krug, Lee M., Pietanza, Maria C., Rizvi, Naiyer A., Pao, William, Kris, Mark G., Riely, Gregory J., Heelan, Robert T., Arcila, Maria E., Miller, Vincent A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4020424/
https://ncbi.nlm.nih.gov/pubmed/20871262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181ec1531
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!